文献速递炎症性肠病

炎症性肠病患者合并2019冠状病毒病的系统综述:是时候进行盘点了

Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-08-07

该系统综述检索截至2020年7月29日的文献,纳入23项研究、243,760例炎症性肠病患者,其中1028例确诊COVID-19,累积患病率0.4%。最常见症状为发热(48.3%)、咳嗽(46.5%)和腹泻(20.5%);30.6%住院,11.4%入住ICU,COVID-19相关死亡29例(3.8%)。作者认为炎症性肠病患者腹泻较非炎症性肠病人群更常见,需进一步研究确定最佳诊疗方案。

要点

  • 炎症性肠病患者中COVID-19累积患病率为0.4%,共1028例确诊。
  • 最常见症状为发热48.3%、咳嗽46.5%、腹泻20.5%。
  • 30.6%患者住院,11.4%入住ICU,COVID-19相关死亡3.8%。

核心结论

  • 炎症性肠病患者合并COVID-19时腹泻较非炎症性肠病人群更常见。
  • 需进一步研究以确定炎症性肠病合并COVID-19患者的最佳诊断-治疗方案。

研究设计与样本

  • 系统综述,检索PubMed、Embase、Web of Science和MedRxiv截至2020年7月29日的文献。
  • 纳入23项报告成人和儿童炎症性肠病合并确诊COVID-19临床信息的研究,共243,760例炎症性肠病患者。

主要发现

  • 1028例患者确诊COVID-19,其中克罗恩病509例(49.5%)、溃疡性结肠炎428例(41.6%)、不确定性结肠炎49例(4.8%)、数据缺失42例(4.1%),累积患病率0.4%。
  • 男性感染多于女性(56.5% vs 39.7%),平均年龄范围14至85岁。
  • 最常见症状为发热(48.3%)、咳嗽(46.5%)和腹泻(20.5%)。
  • 诊断主要依靠鼻咽拭子聚合酶链反应(94.4%)和胸部计算机断层扫描(38.9%)。
  • 最常用药物为羟氯喹(23.9%)、洛匹那韦/利托那韦(8.2%)、类固醇(3.2%)和抗生素(3.1%)。

局限性

  • 需进一步研究以确定炎症性肠病合并COVID-19患者的最佳诊断-治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Data on the clinical characteristics of patients with inflammatory bowel diseases (IBDs) with coronavirus disease 2019 (COVID-19) are scarce. The aim of our systematic review was to investigate symptoms and diagnostic-therapeutic management of IBD patients with COVID-19. METHODS: We searched PubMed, Embase, Web of Science, and MedRxiv up to July 29, 2020, to identify all studies reporting clinical information on adult and pediatric IBD patients with confirmed COVID-19. RESULTS: Twenty-three studies met our inclusion criteria, including 243,760 IBD patients. COVID-19 was diagnosed in 1028 patients (509 with Crohn's disease [49.5%], 428 with ulcerative colitis [41.6%], 49 with indeterminate colitis [4.8%], and 42 with missing data [4.1%]), accounting for a cumulative prevalence of 0.4%. Viral infection occurred more frequently in males than in females (56.5% vs 39.7%), and the mean age ranged from 14 to 85 years. The most common symptoms were fever (48.3%), cough (46.5%), and diarrhea (20.5%), and a COVID-19 diagnosis was achieved mainly through polymerase chain reaction analysis of nasopharyngeal swabs (94.4%) and chest computed tomography scans (38.9%). Hydroxychloroquine (23.9%), lopinavir/ritonavir (8.2%), steroids (3.2%), and antibiotics (3.1%) were the most used drugs. Overall, approximately a third of patients were hospitalized (30.6%), and 11.4% of them required admission to the intensive care unit. In total, 29 COVID-19-related deaths were reported (3.8%), and increasing age and the presence of comorbidities were recognized as risk factors for COVID-19 and negative outcomes. CONCLUSIONS: Diarrhea occurs more frequently in IBD patients with COVID-19 than in the non-IBD population. Further studies are needed to define the optimal diagnostic-therapeutic approach in IBD patients with COVID-19.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. D'Amico F, Danese S, Peyrin-Biroulet L, et al. Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. Clin Gastroenterol Hepatol. 2020. PMID: 32777550. doi:10.1016/j.cgh.2020.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。